Myasthenia Gravis

References

Beers MH, ed. Neuromuscular junction disorders. In Merck Manual-Second Home Edition.

Berrouschot J, Baumann I, et al. Therapy of myasthenic crisis. Crit Care Med. 1997 Jul;25(7):1228–35.

Carandina-Maffeis R, Nucci A, et al. Plasmapheresis in the treatment of myasthenia gravis: Retrospective study of 26 patients. Arq Neuropsiquiatr. 2004 Jun;62(2B):391–5.

Cheng YS, Lu CZ, et al. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies. 1986;5:197–9.

Chiu HC, Chen WH, et al. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher. 2000 Aug;4(4):291–5.

Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci. 1981;377:670–7.

Drachman DB. Myasthenia gravis. N Eng J Med. 1994;330(25):1797–810.

Duan RS, Link H, et al. Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J Clin Immunol. 2003 Mar;23(2):100–6.

Foulks CJ. Myasthenia gravis presenting as laryngeal stridor after exposure to chlorine gas. South Med J. 1981 Nov;74(11):1423–4.

Gelenberg AJ, Doller-Wojcik JC, et al. Choline and lecithin in the treatment of tardive dyskinesia: Preliminary results from a pilot study. Am J Psychiatry. 1979 Jun;136(6):772–6.

Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology. 2000;55(7):15.

Hoch W, McConville J, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001 Mar;7(3):365–8.

Kasper DL, Braunwald E, et al. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Medical Publishing Division; 2005.

Leker RR, Karni A, et al. Exacerbation of myasthenia gravis during the menstrual period. J Neurol Sci. 1998;156(1):107–11.

Lin JH, Hu GY, et al. Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Zhongguo Yao Li Xue Bao. 1997 Jan;18(1):6–10.

Mocchegiani E, Giacconi R, et al. Different age-related effects of thymectomy in myasthenia gravis: Role of thymoma, zinc, thymulin, IL-2 and IL-6. Mech Ageing Dev. 2000 Aug 15;117(1–3):79–91.

Onodera H. The role of the thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med. 2005 Oct;207(2):87–98. Review.

Phillips LH. The epidemiology of myasthenia gravis. Neurologic Clinics of North Am. 1994;12(2):263–71.

Poea-Guyon S, Christadoss P, et al. Effects of cytokines on acetylcholine receptor expression: Implications for myasthenia gravis. J Immunol. 2005 May 15;174(10):5941–9.

Reddi K, Henderson B, et al. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine. 1995 Apr;7(3):287–90.

Roberts PF, Venuta F, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thoracic and Cardiovasc Surg. 2001;122:562–8.

Ronager J, Ravnborg M, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001 Dec;25(12):967–73.

Roxanis I, Micklem K, et al. Thymic myoid cells and germinal center formation in myasthenia gravis: Possible roles in pathogenesis. J Neuroimmunol. 2002 Apr;125(1–2):185–97.

Shiono H, Roxanis I, et al. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci. 2003 Sep;998:237–56.

Stout JR, Eckerson JM, et al. Effects of resistance exercise and creatine supplementation on myasthenia gravis: A case study. Med Sci Sports Exerc. 2001 Jun;33(6):869–72.

Thomas CE, Mayer SA, et al. Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997 May;48(5):1253–60.

van Doorn PA, Brand A, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–12.

Waldbott GL. The preskeletal phase of chronic fluoride intoxication. Fluoride. 1998;31(1):13–20.

Wang R, Yan H, et al. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 Jan;27(1):1–26.

Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg. 2002 Dec;105(1):3–8.

Wurtman RJ, Growdon JH. Dietary enhancement of CNS neurotransmitters. Hosp Pract. 1978 Mar;13(3):71–7.

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.